» Articles » PMID: 34703030

Clonal Populations of a Human TNBC Model Display Significant Functional Heterogeneity and Divergent Growth Dynamics in Distinct Contexts

Abstract

Intratumoral heterogeneity has been described for various tumor types and models of human cancer, and can have profound effects on tumor progression and drug resistance. This study describes an in-depth analysis of molecular and functional heterogeneity among subclonal populations (SCPs) derived from a single triple-negative breast cancer cell line, including copy number analysis, whole-exome and RNA sequencing, proteome analysis, and barcode analysis of clonal dynamics, as well as functional assays. The SCPs were found to have multiple unique genetic alterations and displayed significant variation in anchorage independent growth and tumor forming ability. Analyses of clonal dynamics in SCP mixtures using DNA barcode technology revealed selection for distinct clonal populations in different in vitro and in vivo environmental contexts, demonstrating that in vitro propagation of cancer cell lines using different culture conditions can contribute to the establishment of unique strains. These analyses also revealed strong enrichment of a single SCP during the development of xenograft tumors in immune-compromised mice. This SCP displayed attenuated interferon signaling in vivo and reduced sensitivity to the antiproliferative effects of type I interferons. Reduction in interferon signaling was found to provide a selective advantage within the xenograft microenvironment specifically. In concordance with the previously described role of interferon signaling as tumor suppressor, these findings suggest that similar selective pressures may be operative in human cancer and patient-derived xenograft models.

Citing Articles

Spatial transcriptomics reveals influence of microenvironment on intrinsic fates in melanoma therapy resistance.

Boe R, Triandafillou C, Lazcano R, Wargo J, Raj A bioRxiv. 2024; .

PMID: 39005406 PMC: 11244927. DOI: 10.1101/2024.06.30.601416.


Phenotypic heterogeneity drives differential disease outcome in a mouse model of triple negative breast cancer.

Thankamony A, Ramkomuth S, Ramesh S, Murali R, Chakraborty P, Karthikeyan N Front Oncol. 2023; 13:1230647.

PMID: 37841442 PMC: 10570535. DOI: 10.3389/fonc.2023.1230647.


Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells.

Goyal Y, Busch G, Pillai M, Li J, Boe R, Grody E Nature. 2023; 620(7974):651-659.

PMID: 37468627 PMC: 10628994. DOI: 10.1038/s41586-023-06342-8.


Molecular Characterization and Landscape of Breast cancer Models from a multi-omics Perspective.

Ortiz M, Andrechek E J Mammary Gland Biol Neoplasia. 2023; 28(1):12.

PMID: 37269418 PMC: 10239388. DOI: 10.1007/s10911-023-09540-2.


Integrins and Epithelial-Mesenchymal Cooperation in the Tumor Microenvironment of Muscle-Invasive Lethal Cancers.

Harryman W, Marr K, Nagle R, Cress A Front Cell Dev Biol. 2022; 10:837585.

PMID: 35300411 PMC: 8921537. DOI: 10.3389/fcell.2022.837585.

References
1.
Nowell P . The clonal evolution of tumor cell populations. Science. 1976; 194(4260):23-8. DOI: 10.1126/science.959840. View

2.
Greaves M, Maley C . Clonal evolution in cancer. Nature. 2012; 481(7381):306-13. PMC: 3367003. DOI: 10.1038/nature10762. View

3.
McGranahan N, Swanton C . Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017; 168(4):613-628. DOI: 10.1016/j.cell.2017.01.018. View

4.
Merlo L, Pepper J, Reid B, Maley C . Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006; 6(12):924-35. DOI: 10.1038/nrc2013. View

5.
Tabassum D, Polyak K . Tumorigenesis: it takes a village. Nat Rev Cancer. 2015; 15(8):473-83. DOI: 10.1038/nrc3971. View